NCT00363636终止3 期
A Phase III, Randomized, Double-Blind Study of Galiximab in Combination With Rituximab Compared With Rituximab in Combination With Placebo for the Treatment of Subjects With Relapsed or Refractory, Follicular Non-Hodgkin's Lymphoma
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 终止
- 发起方
- Biogen
- 入组人数
- 340
- 主要终点
- To assess efficacy as measured by progression free survival (PFS), and determine whether rituximab plus galiximab compared to rituximab plus placebo may extend PFS.
研究概览
简要总结
This is a Phase III, multicenter, global, clinical study of an investigational drug called galiximab in combination with an approved drug called rituximab in subjects with follicular NHL.
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with placebo) in subjects with follicular NHL. Safety and pharmacokinetics (PK) of galiximab and rituximab will also be evaluated.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Key Inclusion Criteria:
- •Aged >= 18 years old at the time of informed consent.
- •Histologically confirmed follicular Grade 1-3a NHL.
- •Relapsed or progressive disease after at least 1 prior chemotherapy requiring treatment.
- •Bidimensionally measurable disease with at least 1 lesion >= 2.0 cm in a single dimension.
- •Acceptable hematologic, hepatic, and renal function parameters.
- •Recovered fully from any significant toxicity associated with prior surgery, radiation treatments, chemotherapy, biological therapy, autologous bone marrow or stem cell transplant, or investigational drugs.
排除标准
- •Follicular lymphoma Grade 3b.
- •Rituximab refractory or refractory to anti-CD20 radioimmunotherapy (no response to prior rituximab or prior rituximab-containing regimen, or a response with a TTP of less than 6 months).
- •Cancer radiotherapy, biological therapy, or chemotherapy within 3 weeks prior to Study Day 1 (6 weeks if nitrosourea or mitomycin C).
- •Prior lymphoma vaccine therapy within 12 months prior to Study Day
- •Prior antibody therapy for lymphoma (including radioimmunotherapy) within 6 months prior to Study Day
- •Autologous bone marrow or stem cell transplant within 6 months prior to Study Day
- •Prior allogeneic transplant.
- •Transfusion-dependent subjects.
- •Another primary malignancy requiring active treatment (except hormonal therapy).
- •Serious nonmalignant disease (e.g., congestive heart failure, hydronephrosis); active uncontrolled bacterial, viral, or fungal infections; or other conditions, which would compromise protocol objectives in the opinion of the Investigator and/or the Sponsor.
- •New York Heart Association Class III or IV cardiac disease or myocardial infarction within 6 months prior to Study Day 1.
研究组 & 干预措施
1
Experimental
干预措施: Galiximab in combination with rituximab (Drug)
2
Active Comparator
干预措施: Rituximab in combination with placebo (Drug)
结局指标
主要结局
To assess efficacy as measured by progression free survival (PFS), and determine whether rituximab plus galiximab compared to rituximab plus placebo may extend PFS.
时间窗: The duration of this study is approx 4 years
次要结局
- Secondary efficacy measures include: event-free survival, time to progression, duration of response, complete response rate, and overall survival.(The duration of this study is approx 4 years)
- Safety measures include: adverse event rates, clinical laboratory results, development of anti-galiximab and human anti-chimeric antibodies.(The duration of this study is approx 4 years)
- Pharmacokinetics(The duration of this study is approx 4 years)
- Quality of Life using both the Functional Assessment of Cancer Therapy-Lymphoma (FACT-lym) and the EQ-5D (EuroQoL) instruments(The duration of this study is approx 4 years)
研究者
相似试验
进行中（未招募）
3 期
A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Participants With High-risk Muscle-invasive Bladder Cancer (MIBC) Who Are ctDNA Positive Following CystectomyMuscle-invasive Bladder CancerNCT04660344Hoffmann-La Roche761
招募中
3 期
A Study of Pitolisant in Patients With Prader-Willi SyndromePrader-Willi SyndromeNCT06366464Harmony Biosciences Management, Inc.134
已完成
3 期
Study of Durvalumab With Chemoradiotherapy for Women With Locally Advanced Cervical Cancer (CALLA)Locally Advanced Cervical CancerNCT03830866AstraZeneca770
已完成
3 期
A Study to Evaluate the Efficacy, Response Duration and Safety of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Antihistamine Treatment (H1)Chronic Idiopathic UrticariaNCT01292473Genentech, Inc.323
已完成
3 期
A Study of the Efficacy and Safety of Omalizumab (Xolair) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Antihistamine (H1) TreatmentChronic Idiopathic UrticariaNCT01287117Genentech, Inc.319